Black Friday Sale
Black Friday Sale
HomeNewsTrendsTorrent Pharma a good play on India & US story: CLSA

Torrent Pharma a good play on India & US story: CLSA

In May, the US FDA visited its Indrad facility (the largest facility for Torrent) and handed out Form 483 with 2-3 observations (minor and product related). It was the second inspection in the span of a year on the facility. It is a downside for the company, says CLSA which has a buy call.

April 09, 2021 / 17:46 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Moneycontrol BureauBrokerage house CLSA has raised its price target for Torrent Pharma to Rs 1830 from Rs 1800 and maintained its 'buy' call after the company's fourth quarter earnings, saying the stock was a "good play on the India and US story."Torrent Pharma’s fourth quarter results were largely in line with street expectations. A key metric in the company’s fourth quarter results was its India growth, which was back on track after two subdued quarters, says the CLSA report. India sales grew 13 percent year-on-year to Rs 450 crore."We expect Torrent to build on this base quarter in FY17 driven by 10 new launches in the US, fresh capacities for existing products in the US and EU, and above-industry-average growth in India," says the report, adding, "this should drive a 19 percent core earnings Cagr (compounded annual growth rate) over FY16-18 despite a significantly higher spend on R&D."

    Another positive piece of news for Torrent was the commissioning of the Dahej plant in April. This plant should support growth in the US and EU markets where the pharma company’s running capacity is constrained, adds the report.

    Torrent Pharma reported consolidated net profit of Rs 357 crore for the quarter ended March 31, 2016. It had posted net profit of Rs 130 crore for the January- March period of the previous fiscal.However, a couple of negative surprises revealed the pharma company has more work to do. Torrent has guided for R&D spends to rise to 8 percent of sales in FY17 as against 4 percent in last fiscal year gone by.

    In absolute terms, the brokerage sees an increase of 54 percent in R&D spends in FY17 (40 percent YoY increase in FY16). 

    In May, the US FDA visited its Indrad facility (the largest facility for Torrent) and handed out Form 483 with 2-3 observations (minor and product related). It was the second inspection in the span of a year on the facility.

    first published: May 24, 2016 12:51 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347